People: Epigenomics AG (ECXGk.DE)
1.76EUR
10 Jun 2013
€-0.02 (-1.07%)
€1.78
€1.80
€1.80
€1.75
6,090
14,802
€2.67
€0.73
Staub, Uwe
Brief Biography
Dr. Uwe Staub has been appointed Chief Operating Officer of Epigenomics AG effective from October 1, 2012. Prior to that, he served as Senior Vice President Research and Development / Manufacturing of the Company from November 1, 2008. He was also granted procura and will take over the responsibility for medical affairs and customer support of the Company. He studied Biology at the Julius-Maximilians-Universitaet Wuerzburg, Germany, and earned his Ph.D degree in Biochemistry and Human Genetics. Before joining the Company, Dr. Staub worked 14 years in the IVD industry for Abbott Diagnostics, Digene and Qiagen and gained experience in Operations, Quality and Regulatory Affairs as well as Product Development.
Basic Compensation
| Total Annual Compensation, | Long-Term Incentive Plans, | All Other, | Fiscal Year Total, |
|---|---|---|---|
| -- | -- | -- | -- |
Options Compensation
| Quantity | Market Value | |
|---|---|---|
| Excercisable | -- | -- |
| Unexercisable | -- | -- |
| Excercised | -- | -- |
| Name | Fiscal Year Total |
|---|---|
Heino von Prondzynski |
4,500 |
Thomas Taapken |
168,750 |
Noel Doheny |
-- |
Uwe Staub |
-- |
Albert Weber |
-- |
Juergen Beck |
-- |
Thomson Reuters is the world's largest international multimedia news agency, providing investing news, world news, business news, technology news, headline news, small business news, news alerts, personal finance, stock market, and mutual funds information available on Reuters.com, video, mobile, and interactive television platforms. Thomson Reuters journalists are subject to an Editorial Handbook which requires fair presentation and disclosure of relevant interests.
NYSE and AMEX quotes delayed by at least 20 minutes. Nasdaq delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.
